Evaluating the Safety and Pharmacokinetics of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 Infection

Official Title: Phase I Safety and Pharmacokinetic Study of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 Infection.

<div class="body3 indent2"> <p>The purpose of this study is to evaluate the infectivity, safety, and immunogenicity of the recombinant live-attenuated respiratory syncytial virus (RSV) vaccines RSV ΔNS2/Δ1313/I1314L or RSV 276 or placebo when delivered as nose drops to RSV-seronegative infants 6 to 24 months of age.</p> <p>This study is a companion study to CIR 321.</p> </div>

NCT02778204
Chadwick, Ellen G., MD
Interventional
Yes

Contact Information:

Margaret Sanders, MPH

CRC

312-227-8275